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Introduction {#sec001}
============

Schizophrenia (SZ) is among the most severe and difficult to treat psychiatric disorders due to variable expression of psychotic symptoms, mood deregulation, and cognitive dysfunction\[[@pone.0175209.ref001]\]. There is also considerable heterogeneity in disease heritability, implying that SZ arises from a complex interaction of multiple genetic susceptibility factors; thus, there is no unified pathogenic model \[[@pone.0175209.ref002]\]. Compelling evidence points to disturbances in neurodevelopment during the prenatal and early postnatal periods that impact brain maturation during adolescence and early adulthood, ultimately leading to the delayed emergence of psychiatric symptoms\[[@pone.0175209.ref003]\]. It is thus believed that different allelic combinations of neurodevelopmental genes (haplotypes) may predispose individuals to SZ and other major psychiatric disorders \[[@pone.0175209.ref004], [@pone.0175209.ref005]\].

Neurodevelopmental abnormalities may result from prenatal immune activation \[[@pone.0175209.ref006]\], alimentary deficiency \[[@pone.0175209.ref007]\], and genetic factors. Indeed, multiple genetic factors have been linked to schizophrenia susceptibility\[[@pone.0175209.ref008]--[@pone.0175209.ref010]\], including genes associated with Rho GTPase signaling pathways\[[@pone.0175209.ref011]\]. Rho GTPase activating proteins (RhoGAPs) are a large protein family containing approximate 80 members that stimulate GTP hydrolysis, thereby turning the GTP-bound active form of Rho into a inactive GDP-bound form\[[@pone.0175209.ref012], [@pone.0175209.ref013]\]. The Rho family GTPase play a critical role in many aspects of neuronal development, including neurite outgrowth\[[@pone.0175209.ref014], [@pone.0175209.ref015]\], neuronal differentiation \[[@pone.0175209.ref014]\], axon guidance\[[@pone.0175209.ref015]--[@pone.0175209.ref017]\], and synaptic formation and maintenance\[[@pone.0175209.ref018],[@pone.0175209.ref019]\]. Likewise, many RhoGAP proteins have been linked to neurodevelopmental processes and related disabilities. For example, oligophrenin-1 encodes a RhoGAP involved in X-linked mental retardation \[[@pone.0175209.ref020], [@pone.0175209.ref021]\]. Recently, dysfunction of RhoGAPX-1 and ARHGAP6 has been implicated in a wide range of developmental defects seen in microphthalmia with linear skin defects syndrome\[[@pone.0175209.ref022], [@pone.0175209.ref023]\], while srGAP1, srGAP2, and srGAP3 have been linked to mental retardation, schizophrenia, and seizures\[[@pone.0175209.ref024]\]. Considering the functional redundancy of many RhoGAP proteins, these findings suggest that additional family members are also involved in pathological conditions related to aberrant neurodevelopment.

ARHGAP18 is a newly identified RhoGAP capable of regulating RhoA and RhoC activities in a cell type-specific context \[[@pone.0175209.ref025], [@pone.0175209.ref026]\]. Although the functions of ARHGAP18 in the central nervous system are presently unknown, recent studies have shown a potential correlation between genetic polymorphisms of ARHGAP18 and the occurrence of schizophrenia. Through the combinatorial use of a genome-wide screening and neuroimaging, single nucleotide polymorphisms (SNPs) within *ARHGAP18* were associated with schizophrenia \[[@pone.0175209.ref027], [@pone.0175209.ref028]\]. However, these studies were based on Western populations and not validated in an independent case−control study. Herein, we evaluated the association of *ARHGAP18* polymorphisms and schizophrenia in a large Chinese Han population of SZ patients and matched controls.

Materials and methods {#sec002}
=====================

Subjects {#sec003}
--------

All participants were recruited from northern Henan Province and had four biological grandparents of Han Chinese ancestry. The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition IV (DSM-IV) (1994) Axis I Disorders was used to exclude individuals with a history of severe medical complications (such as diabetes, cardiovascular disease, hypertension), organic brain diseases, concomitant major psychiatric disorders, and/or substance dependence. The discovery cohort consisted of 528 patients (264 males and 264 females; mean age: 27.32 ± 8.03 years old) and 528 healthy controls matched for sex ratio, age, and ethnicity (264 males and 264 females; mean age: 27.73 ± 8.01 years old). The validation cohort consisted of 860 patients (430 males and 430 females; mean age: 28.34 ± 9.25 years old) and 860 healthy matched controls (430 males and 430 females; mean age: 29.58 ± 7.29 years old). For each patient, the diagnosis of SZ was confirmed by at least two psychiatrists according to the DSM-IV criteria for paranoid SZ. All healthy volunteers were recruited from Xinxiang Medical University, Xinxiang city, and surrounding communities and villages by posters in Physical Examination Center and hospitals in towns and counties. Any individual with a personal or family history of mental or neurological diseases was excluded. The controls were well matched to the patient group for gender ratio (1:1 for both groups), age (*F* = 0.621, *P* = 0.464), and ethnicity (all unrelated, living in North Henan Province, and with all biological grandparents of Chinese-Han ancestry).

Written informed consent was obtained for all participants. The study was approved by the ethics committee of the Second Affiliated Hospital of Xinxiang Medical University.

Genotyping {#sec004}
----------

A peripheral blood sample was drawn from each subject into vacutainer tubes containing the anticoagulant ethylenediaminetetraacetic acid. Genomic DNA was extracted from leukocytes using the RelaxGene Blood DNA System (Tiangen Biotech., Beijing, China). In the discovery stage, the genotypes of 35 SNPs in *ARHGAP18* were evaluated using the Illumina GoldenGate assay on a BeadStation 500G Genotyping System (Illumina, Inc., San Diego, CA, USA) according to the manufacturer's instructions.

Validation of specific SNPs, including rs9483050, rs7758025, rs12197901, and rs9492347, was performed using the TaqMan genotyping method according to the manufacturer's protocol, with allelic discrimination and analysis performed on an ABI Prism 7900 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The ABI Taqman probe sequences are listed in [S1 Table](#pone.0175209.s001){ref-type="supplementary-material"}. To evaluate the quality of genotyping, 5% of the samples were randomly selected and re-genotyped. The genotyping consistency rate was more than 98%.

Bioinformatics analyses {#sec005}
-----------------------

All genotype data were examined for cluster separation using Illumina quality scores generated by the software. Poorly performing SNPs as defined by a GenTrain score \< 0.4 or a cluster separation score \< 0.6 were excluded. SNPs were further excluded if controls were not in Hardy---Weinberg equilibrium. As a genotyping quality control, four SNPs were genotyped in duplicate in 100 samples by DNA sequencing.

Genotypes and allele frequencies in SZ and control subjects were compared using the Haploview V4.1 program with Bonferroni correction to exclude type I errors (including from other SNPs in the same GoldenGate 384 assay relevant to a different experimental design). Hardy---Weinberg equilibrium was also evaluated using this program,. The standardized measures of linkage disequilibrium (LD) coefficients (D′), haplotype frequency, haplotype block, and haplotype association were assessed using Haploview V4.1.

Allele and genotype counts were compared by the Pearson chi-square test. A power analysis was performed using the Genetic Power Calculator\[[@pone.0175209.ref029]\]. Genotyping data (include other SNPs in the same GoldenGate 384 assay relevant to a different experimental design) were analyzed using the Markov chain Monte Carlo algorithm in Structure 2.3 \[[@pone.0175209.ref030]\] to generate population stratification assignments for all individuals. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated to evaluate the effect of different alleles and haplotypes on SZ risk. The haplotype frequencies were estimated using the expectation maximization (EM) algorithm.

Results {#sec006}
=======

We selected a total of thirty-five SNPs in *ARHGAP18* for genotypic distribution analysis in 528 patients with schizophrenia and 528 healthy controls. All SNPs evaluated demonstrated a minor allele frequency greater than 5% in the studied samples. Power analysis revealed that the total sample size (n = 1056) had the power (0.86) to detect a small (r = 0.1--0.23) effects and the power (1.00) to detect both medium(r = 0.24--0.36) and large(r \> 0.37) effects on genotype distributions. The genotype and allele frequencies of these SNPs in patients and controls are shown in [Table 1](#pone.0175209.t001){ref-type="table"}.

10.1371/journal.pone.0175209.t001

###### Genotype and allele frequencies of thirty-two SNPs in the ARHGAP18 gene of schizophrenia patients and controls.

![](pone.0175209.t001){#pone.0175209.t001g}

  SNP\#   dbSNP ID     Allele(D/d)[^a^](#t001fn001){ref-type="table-fn"}   Patients   Controls   *P*-value                                                                                       
  ------- ------------ --------------------------------------------------- ---------- ---------- ----------- ----- ----- ------- ----- --------- ----- ----- ----- ------- --------------------- ---------------------
  1       rs6569610    A/T                                                 527        0.931      304         193   30    0.240   527   0.109     293   209   25    0.246   0.524                 0.761
  2       rs9492347    A/G                                                 528        \<0.001    480         41    7     0.052   528   0.821     460   66    2     0.066   **0.011**             0.167
  3       rs6923483    A/G                                                 527        0.451      262         214   51    0.300   527   0.646     279   206   42    0.275   0.458                 0.211
  4       rs4895852    G/A                                                 527        0.719      178         260   89    0.416   527   0.908     163   259   105   0.445   0.371                 0.172
  5       rs7758025    G/A                                                 528        0.041      417         99    12    0.116   528   0.213     463   61    4     0.065   **0.0002**            **4.36×10**^**−5**^
  6       rs9385502    G/A                                                 527        0.203      277         218   32    0.268   527   0.305     270   221   36    0.278   0.841                 0.591
  7       rs9402145    A/G                                                 528        0.445      390         130   8     0.138   528   0.708     388   128   12    0.144   0.663                 0.708
  8       rs3813366    A/G                                                 527        0.950      139         264   124   0.486   527   0.436     164   252   111   0.450   0.216                 0.097
  9       rs17057516   A/G                                                 514        \<0.001    383         94    37    0.163   512   \<0.001   375   106   31    0.164   0.514                 0.969
  10      rs9483048    A/T                                                 525        0.970      207         245   73    0.372   528   0.671     218   246   64    0.354   0.647                 0.385
  11      rs11753915   C/A                                                 528        0.852      359         152   17    0.176   528   0.364     338   173   17    0.196   0.370                 0.240
  12      rs9483050    A/G                                                 528        0.194      379         132   17    0.157   528   0.551     442   81    5     0.086   **7.54×10**^**−6**^   **5.98×10**^**−7**^
  13      rs12216321   A/G                                                 525        \<0.001    429         72    24    0.114   525   \<0.001   428   81    16    0.108   0.344                 0.627
  14      rs13193932   C/G                                                 528        \<0.001    97          388   43    0.449   528   \<0.001   80    417   31    0.454   0.099                 0.827
  15      rs12197901   A/G                                                 528        0.339      364         145   19    0.173   528   0.452     395   121   12    0.137   0.082                 **0.022**
  16      rs9388722    A/G                                                 527        0.336      158         251   118   0.462   528   0.296     155   273   100   0.448   0.296                 0.514
  17      rs10499164   G/A                                                 528        0.011      456         65    7     0.075   528   0.447     445   78    5     0.083   0.438                 0.468
  18      rs9388723    A/G                                                 527        0.889      288         204   35    0.260   528   0.169     262   229   37    0.287   0.256                 0.164
  19      rs7765511    A/G                                                 528        0.378      489         39    0     0.037   526   0.924     479   46    1     0.046   0.433                 0.316
  20      rs12202304   C/A                                                 526        0.995      481         44    1     0.044   528   0.224     475   53    0     0.050   0.393                 0.483
  21      rs6928167    G/A                                                 527        0.050      160         240   127   0.469   528   0.427     166   252   110   0.447   0.445                 0.317
  22      rs11968342   G/C                                                 528        0.165      418         107   3     0.107   527   0.863     409   111   7     0.119   0.413                 0.400
  23      rs10872345   A/G                                                 528        0.507      236         239   53    0.327   528   0.325     251   233   44    0.304   0.503                 0.261
  24      rs9398917    G/A                                                 528        0.832      323         181   24    0.217   528   0.385     348   165   15    0.185   0.153                 0.064
  25      rs1476042    C/A                                                 528        0.160      175         244   109   0.438   528   0.524     185   261   82    0.402   0.097                 0.103
  26      rs11962358   A/G                                                 527        0.417      211         238   78    0.374   527   0.783     191   250   86    0.400   0.432                 0.211
  27      rs17467757   G/A                                                 527        0.452      400         116   11    0.131   528   0.481     400   117   11    0.132   0.998                 0.962
  28      rs763132     A/C                                                 527        0.783      191         250   86    0.400   528   0.143     189   240   99    0.415   0.569                 0.501
  29      rs17057659   G/A                                                 527        0.408      285         200   42    0.269   528   0.396     276   206   46    0.282   0.813                 0.512
  30      rs6917887    G/A                                                 527        0.924      183         256   88    0.410   528   0.106     173   274   81    0.413   0.554                 0.888
  31      rs11154495   C/A                                                 527        0.274      242         222   63    0.330   528   0.647     241   228   59    0.328   0.899                 0.902
  32      rs3752536    G/A                                                 521        0.052      324         164   33    0.221   525   0.859     325   177   23    0.212   0.322                 0.643
  33      rs17057685   C/A                                                 528        0.323      291         196   41    0.263   528   0.453     272   209   47    0.287   0.480                 0.223
  34      rs11154496   G/A                                                 528        0.425      446         80    2     0.080   528   0.020     453   68    7     0.078   0.149                 0.871
  35      rs9402163    C/G                                                 527        0.231      351         153   23    0.189   528   0.676     368   144   16    0.167   0.381                 0.183

^a^ Major/minor allele, major and minor alleles are denoted by D and d, respectively.

^b^ Number of samples which are well genotyped.

^c^ the significance of bold values is p\<0.05.

The genotype and allelic frequencies of two SNPs, rs7758025 and rs9483050 displayed significant differences between the case and control groups (rs7758025: genotype *P* = 0.0002; allele *P* = 4.36×10^-5^; rs9483050: genotype *P* = 7.54×10^-6^; allele *P* = 5.98×10^-7^). In addition, rs9492347 genotype frequency was associated with schizophrenia (*P* = 0.011) as was rs12197901 allelic frequency (*P* = 0.022). The genotypic distribution of these four SNPs did not demonstrate significant deviations from Hardy−Weinberg equilibrium in the control group.

We next performed LD analysis using pairs of SNPs to further analyze the haplotype structure. As shown in [Fig 1](#pone.0175209.g001){ref-type="fig"}, [Table 2](#pone.0175209.t002){ref-type="table"}, the LD plot consisted of thrity-five SNPs. Haplotypes GG and GA in the LD block rs7758025−rs9385502 showed minimal difference between the case and control groups (*P* = 0.175 and *P* = 0.232, respectively), while haplotype AG was strongly associated with schizophrenia (*P* = 0.0012, *OR* = 0.67, 95% *CI* = 0.48−0.93). These associations remained following a 1000-times random permutation test (*P* = 0.022). Haplotype CG in the LD block rs11753915−rs9483050 was also associated with schizophrenia (*P* = 9.6×10^−6^, *OR* = 0.58, 95% *CI* = 0.44−0.78) even after Bonferroni correction (*P* = 0.0001).

10.1371/journal.pone.0175209.t002

###### Haplotype analysis among SZ and controls.

![](pone.0175209.t002){#pone.0175209.t002g}

  Haplotype[^a^](#t002fn001){ref-type="table-fn"}   Haplotype frequencies[^b^](#t002fn002){ref-type="table-fn"}   χ^2^           *P*-value[^c^](#t002fn003){ref-type="table-fn"}   OR (95% CI)          
  ------------------------------------------------- ------------------------------------------------------------- -------------- ------------------------------------------------- -------------------- -------------------
  rs7758025--rs9385502                                                                                                                                                                                  
  GG                                                666.6(63.1)                                                   696.4(65.9)    1.837                                             0.175                1.00
  GA                                                266.4(25.2)                                                   290.6 (27.5)   1.429                                             0.232                1.06 (0.86--1.30)
  AG                                                106.8(10.1)                                                   66.0(6.3)      10.489                                            0.0012(0.022)        0.67 (0.48--0.93)
  rs11753915--rs9483050                                                                                                                                                                                 
  CA                                                716.8(67.9)                                                   760.6(72.0)    4.323                                             0.038                1.00
  AA                                                173.2(16.4)                                                   204.4(19.4)    3.138                                             0.077                1.12 (0.88--1.41)
  CG                                                153.2(14.5)                                                   88.4(8.4)      19.628                                            9.6×10^−6^(0.0001)   0.58 (0.44--0.78)

^a^ Haplotypes were omitted from analysis if the estimated haplotype probabilities were less than 5%.

^b^ Frequencies are shown in parenthesis (%).

^c^ *P* values in the parenthesis were analyzed with 1000 random permutations, Global haplotype association *P*-value all \<0.0001.

![LD structure and the D′ values for the 31 Single Nucleotide Polymorphisms (SNPs).](pone.0175209.g001){#pone.0175209.g001}

We then re-tested the four *ARHGAP18* SNPs associated with schizophrenia in an independent validation cohort of 860 patients and 860 controls. In stage 2, the ample size gets a high power (0.93). As shown in [Table 3](#pone.0175209.t003){ref-type="table"}, both genotype and allelic frequencies of rs7758025 and rs9483050 SNPs displayed strong associations with schizophrenia in the validation cohort. Of note, rs9483050 appeared most strongly associated with the disease state across the two cohorts. In addition, the allelic frequency of rs12197901 remained associated with schizophrenia in the combined analysis (*P* = 0.021), although not in the validation cohort alone (*P* = 0.251). The trends observed for the association of rs9492347 with SZ were not confirmed in the validation cohort or combined analysis.

10.1371/journal.pone.0175209.t003

###### SNP association analysis for ARHGAP18 in stage 2 and combined sample set.

![](pone.0175209.t003){#pone.0175209.t003g}

  Stage   dbSNP ID     Allele(D/d)[^a^](#t003fn001){ref-type="table-fn"}   Patients   Controls   *P*-value                                                                             
  ------- ------------ --------------------------------------------------- ---------- ---------- ----------- ----- ---- ------- ------ ------- ------ ----- ---- ------- ------------- --------------
  1       rs9492347    A/G                                                 528        \<0.001    480         41    7    0.052   528    0.821   460    66    2    0.066   0.011         0.167
  2                                                                        855        0.001      733         110   12   0.078   860    0.009   742    108   10   0.074   0.886         0.664
  1&2                                                                      1383       \<0.001    1213        151   19   0.068   1388   0.045   1202   174   12   0.071   0.196         0.662
  1       rs7758025    G/A                                                 528        0.041      417         99    12   0.116   528    0.213   463    61    4    0.065   2.00×10^−4^   4.36×10^−5^
  2                                                                        860        0.006      679         161   20   0.117   860    0.935   714    139   7    0.089   0.013         0.007
  1&2                                                                      1388       \<0.001    1096        260   32   0.117   1388   0.439   1177   200   11   0.080   2.79×10^−5^   4.28×10^−6^
  1       rs9483050    A/G                                                 528        0.194      379         132   17   0.157   528    0.551   442    81    5    0.086   7.54×10^−6^   5.98×10^−7^
  2                                                                        860        0.002      646         186   28   0.141   860    0.529   709    142   9    0.093   9.20×10^−5^   1.35×10^−5^
  1&2                                                                      1388       0.001      1025        318   45   0.147   1388   0.387   1151   223   14   0.090   1.80×10^−9^   7.28×10^−11^
  1       rs12197901   A/G                                                 528        0.339      364         145   19   0.173   528    0.452   395    121   12   0.137   0.082         0.022
  2                                                                        860        0.217      593         236   31   0.173   860    0.67    607    233   20   0.159   0.845         0.251
  1&2                                                                      1388       0.119      957         381   50   0.173   1388   0.911   1002   354   32   0.151   0.050         0.021

^a^ Major/minor allele, major and minor alleles are denoted by D and d, respectively.

^b^ Number of samples which are well genotyped.

Discussion {#sec007}
==========

Herein, we describe associations between *ARHGAP18* polymorphisms and schizophrenia in a Chinese Han population. In stage one, we screened SNPs in *ARHGAP18* from GWAS data, and discovered four SNPs, rs7758025, rs9483050, rs9492347 and rs12197901, associated with schizophrenia. In stage two, we validated our findings in an independent cohort and demonstrated that rs9483050 is strongly associated with schizophrenia. Our data suggest that allelic variation in the *ARHGAP18* gene may confer vulnerability to SZ in the Chinese Han population, providing additional evidence for the involvement of disrupted neurodevelopmental signals in disease pathogenesis.

Although the detailed molecular events during SZ progression remain elusive, it is widely accepted that abnormalities in early brain development caused by inherited genetic variants alter critical developmental and maturational processes, resulting in eventual emergence of disabling psychoses\[[@pone.0175209.ref031]--[@pone.0175209.ref033]\]. A plethora of genes have polymorphisms associated with SZ \[[@pone.0175209.ref009], [@pone.0175209.ref034]--[@pone.0175209.ref038]\]. Nevertheless, due to complexity of epidemiology, including ethnicity and disease subtype, our understanding of disease heritability remains limited and it is likely that many more SZ susceptibility genes remain to be identified.

*ARHGAP18* (6q22.33) lies within a previously reported SZ candidate region (SCR) identified by Lerer et al \[[@pone.0175209.ref039]\], in an ethnically homogeneous family-based Arab---Israeli sample \[[@pone.0175209.ref027], [@pone.0175209.ref028]\]. There are 134 genes in this risk region, of which several contain SNPs enriched in sporadic SZ cases, such as dystrobrevin-binding protein 1 (DTNBP1) and laminin alpha-2 (LAMA2). Given the large genomic distance spanned and the difference in localization of linkage peaks, it is possible that this region harbors additional SZ susceptibility genes, one of which may be *ARHGAP18*. In fact, there are several reports on the involvement of *ARHGAP18* SNPs in human diseases, including SZ. Recurrent chromosomal imbalances affecting the *ARHGAP18* locus were observed in six of nine patients with neurofibromatosis type 1\[[@pone.0175209.ref040]\]. Also, Potkin *et al*. used brain activation pattern during a working memory task as a quantitative trait to interpret GWAS data and identified *ARHGAP18* as a SZ risk gene \[[@pone.0175209.ref027]\]. Specifically, they found six SNPs within *ARHGAP18*, rs12664247, rs4509146, rs11154490, rs2051632, rs17469847 and rs10484284, with statistically significant relationships in both the discovery and validation cohorts.

Herein, we used large discovery and validation cohorts to identify the rs9492347, rs7758025, and rs9483050 SNPs of *ARHGAP18* as susceptibility loci for SZ. Our results are intriguing in several ways. First, these SNPs were not associated with SZ in GWASs interrogating *ARHGAP18*, although those studies did not use the sample SNP panel studied here. Also, the number of included samples in our study is much higher than previous studies on *ARHGAP18* SNPs. Moreover, our study extends the risk of SZ conferred by *ARHGAP18* SNPs from Western populations to the Eastern Han population.

*ARHGAP18* encodes one of approximately 80 RhoGAP proteins \[[@pone.0175209.ref012], [@pone.0175209.ref013]\]. As a RhoGAP, ARHGAP18 mainly serves as a molecular switch for controlling the balance between active and inactive Rho proteins to regulate Rho-mediated signaling pathways. Rho GTPases, a protein family composed of 22 members in mammals, are known as important modulators of the actin cytoskeleton influencing neuronal morphology and migration \[[@pone.0175209.ref041], [@pone.0175209.ref042]\]. In addition, Rho GTPases are also reportedly involved in the regulation of growth factor-linked signal pathways.

Among members of the Rho GTPase family, RhoA is the main molecule responding to ARHGAP18 regulation. ARHGAP18-knockdown cells demonstrated impaired cell spreading, premature formation of stress fibers, and sustained activation of RhoA upon cell attachment, resulting in inhibition of cell migration \[[@pone.0175209.ref025], [@pone.0175209.ref026]\]. Although the neurodevelopmental function of ARHGAP18 has not been elucidated, numerous studies have suggested a critical role for RhoA in neurogenesis and maturation \[[@pone.0175209.ref043]--[@pone.0175209.ref046]\]. Abolishing RhoA activity in the postnatal stage led to major changes in density and absolute number of neurons in the somatosensory cortex \[[@pone.0175209.ref047]\]. Also, deletion of RhoA from neural progenitor cells in mice resulted in abnormal locomotor behavior \[[@pone.0175209.ref048], [@pone.0175209.ref049]\]. Of note, all three identified SNPs are located in the intron region, which is common for most top hit SZ-associated SNPs revealed by GWASs. The presence of these intronic SNPs may regulate ARHGAP18 mRNA splicing in a trans-acting manner, thereby leading to malfunction of the ARHGAP18−RhoA axis in neurodevelopment.

Conclusion {#sec008}
==========

In summary, our study provides novel data suggesting an association between ARHGAP18 and SZ susceptibility. Replication studies in different ethnic populations, particularly in patients with defined SZ phenotypes, and more samples, are required to confirm the role of ARHGAP18 variants in SZ.

Supporting information {#sec009}
======================

###### Taqman probe sequences of four SNPs.
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Click here for additional data file.
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